Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 3 Date: 26 Aug 2024
Reviewer's report:
Review of the manuscript:
Risk of clostridium difficile infection in inflammatory bowel Disease patients undergoing
vedolizumab treatment: a systematic review and meta-analysis
Thank you again for the kind invitation.
I have read the detailed response of the authors to the comments of all reviewers. I am pretty
happy with their response on my part. I therefore agree for this manuscript to be published in
its revised version.
Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 3 Date: 26 Aug 2024
Reviewer's report:
Review of the manuscript:
Risk of clostridium difficile infection in inflammatory bowel Disease patients undergoing
vedolizumab treatment: a systematic review and meta-analysis
Thank you again for the kind invitation.
I have read the detailed response of the authors to the comments of all reviewers. I am pretty
happy with their response on my part. I therefore agree for this manuscript to be published in
its revised version.
Please review this paper.
user
Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 3 Date: 26 Aug 2024
Reviewer's report:
Review of the manuscript:
Risk of clostridium difficile infection in inflammatory bowel Disease patients undergoing
vedolizumab treatment: a systematic review and meta-analysis
Thank you again for the kind invitation.
I have read the detailed response of the authors to the comments of all reviewers. I am pretty
happy with their response on my part. I therefore agree for this manuscript to be published in
its revised version.
assistant